Stay updated on AVA6000 in Solid Tumours Clinical Trial
Sign up to get notified when there's something new on the AVA6000 in Solid Tumours Clinical Trial page.
Latest updates to the AVA6000 in Solid Tumours Clinical Trial page
- Check7 days agoChange DetectedThe study page appears unchanged in core content such as eligibility criteria and locations; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check14 days agoChange DetectedAdded details of the Phase 1a 3+3 dose-escalation design for AVA6000 with Q3W and Q2W schedules and the Phase 1b dose expansion with an RDE-1 cohort to identify the optimal biologic dose. It also notes AVA6000 as a FAP-activated doxorubicin and updates the cardiac safety assessment to include cumulative exposure to doxorubicin.SummaryDifference1%
- Check21 days agoChange DetectedAdded a site-wide notice about government funding status and NIH CC operations, and updated CMS to version v3.4.1. The previous CMS version v3.4.0 was removed.SummaryDifference0.4%
- Check28 days agoChange DetectedAdds a glossary display and new study-record metadata fields: Last Update Submitted that Met QC Criteria and Last Update Posted, along with No FEAR Act Data and a Revision: v3.4.0 note. Removes older QC-related labels (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, Revision: v3.3.4) and, to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check42 days agoChange DetectedThe update is a minor revision from v3.3.3 to v3.3.4 and does not modify substantive study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check64 days agoChange DetectedAdded study sites in New York, Texas, and Washington and included Dr Jennifer Specht as Principal Investigator. Updated TNBC eligibility to allow any prior therapy with BRCA wild-type and removed the previous site list and the TNBC criteria restricting to up to 3 lines of prior therapy and BRCA PD-L1 negative.SummaryDifference0.7%
Stay in the know with updates to AVA6000 in Solid Tumours Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AVA6000 in Solid Tumours Clinical Trial page.